SEOUL — Yuhan, a South Korean pharmaceutical and chemical company, will push for the development of new drug platform technologies based on messenger ribonucleic acid (mRNA) in cooperation with U.S. and Quran University research teams from around the world. South.
mRNA is a transient intermediary between genes and proteins. It has emerged as a new class of therapeutic agent to prevent and treat various diseases. To function in vivo, mRNA requires safe, efficient and stable delivery systems such as lipid nanoparticles (LNP), the most clinically advanced non-viral gene delivery system.
Yuhan said he would work with a research team led by Lee Hyuk-jin, professor of pharmaceutical sciences at Ewha Woman University in Seoul, to develop the mRNA source technology. mRNA is less stable and easily broken down in the body. Yuhan aims to develop a new type of mRNA structure capable of increasing protein expression.
In separate cooperation with a research team led by Lee Joo-youp of the University of Cincinnati, Yuhan would develop new LNP source technology that increases delivery efficiency.
Yuhan is responsible for the preclinical and clinical development of new drugs such as mRNA-based immuno-cancer drugs using original technologies secured through joint research. The company would expand the scope of mRNA applications to treat various diseases.
© Aju Business Daily & www.ajunews.com Copyright: Nothing on this site may be reproduced, distributed, transmitted, displayed, published or broadcast without the permission of Aju News Corporation.